{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:30:16Z","timestamp":1794000616362,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40265-018-0991-6","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T10:45:56Z","timestamp":1539168356000},"page":"1605-1613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia"],"prefix":"10.1007","volume":"78","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"issue":"1","key":"991_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1313341","volume":"373","author":"ML Gumz","year":"2015","unstructured":"Gumz ML, Rabinowitz L, Wingo CS. An integrated view of potassium homeostasis. N Engl J Med. 2015;373(1):60\u201372.","journal-title":"N Engl J Med."},{"issue":"1","key":"991_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10557-017-6767-5","volume":"32","author":"J Tamargo","year":"2018","unstructured":"Tamargo J, Caballero R, Delp\u00f3n E. New therapeutic approaches for the treatment of hyperkalaemia in patients treated with renin-angiotensin-aldosterone system inhibitors. Cardiovasc Drugs Ther. 2018;32(1):99\u2013119.","journal-title":"Cardiovasc Drugs Ther."},{"issue":"21","key":"991_CR3","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/jama.2014.15736","volume":"312","author":"BS Dixon","year":"2014","unstructured":"Dixon BS. Zirconium cyclosilicate for treatment of hyperkalaemia. JAMA. 2014;312(21):2217\u20138.","journal-title":"JAMA."},{"key":"991_CR4","unstructured":"UK Renal Association. Clinical practice guidelines: treatment of acute hyperkalaemia in adults. 2014. http:\/\/www.renal.org . Accessed 3 Aug 2018."},{"issue":"2","key":"991_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","volume":"93","author":"PI Georgianos","year":"2018","unstructured":"Georgianos PI, Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding drugs. Kidney Int. 2018;93(2):325\u201334.","journal-title":"Kidney Int."},{"issue":"2","key":"991_CR6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jemermed.2018.04.004","volume":"55","author":"B Long","year":"2018","unstructured":"Long B, Warix JR, Koyfman A. Controversies in management of hyperkalaemia. J Emerg Med. 2018;55(2):192\u2013205.","journal-title":"J Emerg Med."},{"issue":"6","key":"991_CR7","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1053\/j.ajkd.2017.09.003","volume":"70","author":"CP Kovesdy","year":"2017","unstructured":"Kovesdy CP, Appel LJ, Grams ME, et al. Potassium homeostasis in health and disease: a scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension. Am J Kidney Dis. 2017;70(6):844\u201358.","journal-title":"Am J Kidney Dis."},{"key":"991_CR8","unstructured":"AstraZeneca. Lokelma (sodium zirconium cyclosilicate) for oral suspension: EU summary of product characteristics. 2018. http:\/\/www.ema.europa.eu\/ema\/ . Accessed 3 Aug 2018."},{"key":"991_CR9","unstructured":"AstraZeneca. Lokelma\u2122 (sodium zirconium cyclosilicate) for oral suspension: US prescribing information. 2018. http:\/\/www.fda.gov\/ . Accessed 3 Aug 2018."},{"issue":"12","key":"991_CR10","doi-asserted-by":"publisher","first-page":"e114686","DOI":"10.1371\/journal.pone.0114686","volume":"9","author":"F Stavros","year":"2014","unstructured":"Stavros F, Yang A, Leon A, et al. Characterization of structure and function of ZS-9, a K\u2009+\u2009selective ion trap. PLoS One. 2014;9(12):e114686.","journal-title":"PLoS One."},{"issue":"Suppl.","key":"991_CR11","first-page":"342","volume":"17","author":"F Zannad","year":"2015","unstructured":"Zannad F, Rasmussen HS, Lavin PT, et al. Effect of sodium zirconium cyclosilicate (ZS-9) on aldosterone from the phase 3 randomized, double-blind, placebo-controlled HARMONIZE study [abstract no. P1592]. Eur J Heart Fail. 2015;17(Suppl.):342.","journal-title":"Eur J Heart Fail"},{"key":"991_CR12","unstructured":"European Medicines Agency. Sodium zirconium cyclosilicate: EU assessment report. 2018. http:\/\/www.ema.europa.eu\/ema\/ . Accessed 3 Aug 2018."},{"issue":"2","key":"991_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/ki.2014.382","volume":"88","author":"SR Ash","year":"2015","unstructured":"Ash SR, Singh B, Lavin PT, et al. A phase 2 study on the treatment of hyperkalaemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015;88(2):404\u201311.","journal-title":"Kidney Int."},{"issue":"3","key":"991_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"DK Packham","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalaemia. N Engl J Med. 2015;372(3):222\u201331.","journal-title":"N Engl J Med."},{"issue":"21","key":"991_CR15","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28\u00a0days among outpatients with hyperkalaemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223\u201333.","journal-title":"JAMA."},{"key":"991_CR16","unstructured":"Data on file, AstraZeneca, 2018."},{"issue":"10","key":"991_CR17","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/ejhf.300","volume":"17","author":"SD Anker","year":"2015","unstructured":"Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015;17(10):1050\u20136.","journal-title":"Eur J Heart Fail."},{"key":"991_CR18","doi-asserted-by":"crossref","unstructured":"Kosiborod M, McCullough PA, Rasmussen H, et al. Acute efficacy of sodium zirconium cyclosilicate (ZS-9) in patients on mineralocorticoid-receptor antagonists: analysis from two phase 3 studies. Circulation 2015;132(Suppl 3).","DOI":"10.1161\/circ.132.suppl_3.13555"},{"key":"991_CR19","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT02107092. 2016. http:\/\/clinicaltrials.gov\/ . Accessed 3 Aug 2018."},{"issue":"Suppl","key":"991_CR20","first-page":"390","volume":"28","author":"S Fishbane","year":"2017","unstructured":"Fishbane S, Adler S, Singh B, et al. Maintained efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: 12-month, open-label, phase 3 study [abstract no. TH-PO1112]. J Am Soc Nephrol. 2017;28(Suppl):390.","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"991_CR21","first-page":"585","volume":"71","author":"BS Spinowitz","year":"2018","unstructured":"Spinowitz BS, Pergola PE, Lerma EV, et al. Initial response rates for sodium zirconium cyclosilicate treatment of hyperkalaemia [abstract no. 281]. Am J Kidney Dis. 2018;71(4):585\u20136.","journal-title":"Am J Kidney Dis."},{"issue":"Suppl 1","key":"991_CR22","doi-asserted-by":"publisher","first-page":"i72","DOI":"10.1093\/ndt\/gfy104.FP071","volume":"33","author":"S Roger","year":"2018","unstructured":"Roger S, Lavin P, Lemma E, et al. Safety and efficacy of sodium zirconium cyclosilicate for long-term treatment of hyperkalaemia in patients with chronic kidney disease: results from an open-label, phase 3 study [abstract no. FP071]. Nephrol Dial Transplant. 2018;33(Suppl 1):i72.","journal-title":"Nephrol Dial Transplant."},{"issue":"Suppl 1","key":"991_CR23","doi-asserted-by":"publisher","first-page":"i489","DOI":"10.1093\/ndt\/gfy104.SP421","volume":"33","author":"S Fishbane","year":"2018","unstructured":"Fishbane S, Roger S, Packham D, et al. Sodium zirconium cyclosilicate for hyperkalaemia in patients with diabetes mellitus: retrospective analysis of a 12\u00a0month open label, phase 3 study [abstract no. SP421]. Nephrol Dial Transplant. 2018;33(Suppl 1):i489\u201390.","journal-title":"Nephrol Dial Transplant."},{"issue":"Suppl 1","key":"991_CR24","first-page":"A16610","volume":"136","author":"P McCullough","year":"2017","unstructured":"McCullough P, Pergola P, Fishbane S, et al. Efficacy and safety of sodium zirconium cyclosilicate to treat hyperkalaemia among patients taking renin-angiotensin-aldosterone system inhibitors in a 12-month open-label, phase 3 study: a post hoc subgroup analysis [abstract no. 16610]. Circulation. 2017;136(Suppl 1):A16610.","journal-title":"Circulation"},{"issue":"Suppl","key":"991_CR25","first-page":"390","volume":"28","author":"D Packham","year":"2017","unstructured":"Packham D, Roger S, Pergola P, et al. Acute efficacy of sodium zirconium cyclosilicate for hyperkalaemia in outpatients with potassium\u2009\u2265\u20096.0\u00a0mEq\/L: post-hoc subgroup analysis of a phase 3 trial [abstract no. TH-PO1113]. J Am Soc Nephrol. 2017;28(Suppl):390.","journal-title":"J Am Soc Nephrol."},{"key":"991_CR26","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT02163499. 2018. http:\/\/clinicaltrials.gov\/ . Accessed 3 Aug 2018."},{"key":"991_CR27","unstructured":"US FDA Center for Drug Evaluation and Research. Medical review(s). 2017. http:\/\/www.fda.gov\/ . Accessed 3 Aug 2018."},{"key":"991_CR28","unstructured":"Vifor France. Veltassa (patiromer): EU summary of product characteristics. 2017. http:\/\/www.ema.europa.eu . Accessed 3 Aug 2018."}],"updated-by":[{"DOI":"10.1007\/s40265-019-01097-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0991-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0991-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0991-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T18:50:38Z","timestamp":1662231038000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0991-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":28,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["991"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0991-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"10 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia, written by Sheridan M. Hoy, was originally published Online First without open access.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2019","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia, written by Sheridan M. Hoy, was originally published Online First without open access.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia, written by Sheridan M. Hoy, was originally published Online First without open access.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia, written by Sheridan M. Hoy, was originally published Online First without open access.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sheridan Hoy is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}